Literature DB >> 21258861

Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer.

Jennifer L Clark1, Karen Dresser, Chung-Cheng Hsieh, Michael Sabel, Celina G Kleer, Ashraf Khan, Leslie M Shaw.   

Abstract

Recent studies have identified a role for insulin receptor substrate-2 (IRS-2) in promoting motility and metastasis in breast cancer. However, no published studies to date have examined IRS-2 expression in human breast tumors. We examined IRS-2 expression by immunohistochemistry (IHC) in normal breast tissue, benign breast lesions, and malignant breast tumors from the institutional pathology archives and a tumor microarray from a separate institution. Three distinct IRS-2 staining patterns were noted: diffusely cytoplasmic, punctate cytoplasmic, and localized to the cell membrane. The individual and pooled datasets were analyzed for associations of IRS-2 staining pattern with core clinical parameters and clinical outcomes. Univariate analysis revealed a trend toward decreased overall survival (OS) with IRS-2 membrane staining, and this association became significant upon multivariate analysis (P = 0.01). In progesterone receptor negative (PR-) tumors, in particular, IRS-2 staining at the membrane correlated with significantly worse OS than other IRS-2 staining patterns (P < 0.001). When PR status and IRS-2 staining pattern were evaluated in combination, PR- tumors with IRS-2 at the membrane were associated with a significantly decreased OS when compared with all other combinations (P = 0.002). Evaluation of IRS-2 staining patterns could potentially be used to identify patients with PR- tumors who would most benefit from aggressive treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258861      PMCID: PMC3128655          DOI: 10.1007/s10549-011-1353-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  47 in total

1.  Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells.

Authors:  L Mauro; M Salerno; M L Panno; D Bellizzi; D Sisci; A Miglietta; E Surmacz; S Andò
Journal:  Biochem Biophys Res Commun       Date:  2001-11-02       Impact factor: 3.575

2.  Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture.

Authors:  R W Furlanetto; J N DiCarlo
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

3.  Involvement of insulin receptor substrate 2 in mammary tumor metastasis.

Authors:  Julie A Nagle; Zhefu Ma; Maura A Byrne; Morris F White; Leslie M Shaw
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

4.  Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene.

Authors:  L Vassen; W Wegrzyn; L Klein-Hitpass
Journal:  Mol Endocrinol       Date:  1999-03

Review 5.  Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

Authors:  Xiaojiang Cui; Rachel Schiff; Grazia Arpino; C Kent Osborne; Adrian V Lee
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

6.  Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells.

Authors:  Marilena Lanzino; Cecilia Garofalo; Catia Morelli; Maria Le Pera; Ivan Casaburi; Michael J McPhaul; Eva Surmacz; Sebastiano Andò; Diego Sisci
Journal:  Breast Cancer Res Treat       Date:  2008-06-04       Impact factor: 4.872

7.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

Authors:  A V Lee; J G Jackson; J L Gooch; S G Hilsenbeck; E Coronado-Heinsohn; C K Osborne; D Yee
Journal:  Mol Endocrinol       Date:  1999-05

8.  Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression.

Authors:  Xihong Zhang; Sailaja Kamaraju; Fumihiko Hakuno; Tomohiro Kabuta; Shin-Ichiro Takahashi; Deepali Sachdev; Douglas Yee
Journal:  Breast Cancer Res Treat       Date:  2004-01       Impact factor: 4.872

9.  Modulation of growth hormone signal transduction in kidneys of streptozotocin-induced diabetic animals: effect of a growth hormone receptor antagonist.

Authors:  Ana C P Thirone; John A Scarlett; Alessandra L Gasparetti; Eliana P Araujo; Maria H L Lima; Carla R O Carvalho; Lício A Velloso; Mario J A Saad
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

10.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

View more
  7 in total

1.  Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2.

Authors:  Jose Mercado-Matos; Jenny Janusis; Sha Zhu; Samuel S Chen; Leslie M Shaw
Journal:  Mol Cell Biol       Date:  2018-06-28       Impact factor: 4.272

2.  IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma.

Authors:  Sha Zhu; B Marie Ward; Jun Yu; Asia N Matthew-Onabanjo; Jenny Janusis; Chung-Cheng Hsieh; Keith Tomaszewicz; Lloyd Hutchinson; Lihua Julie Zhu; Dina Kandil; Leslie M Shaw
Journal:  JCI Insight       Date:  2018-04-19

3.  Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells.

Authors:  Jose Mercado-Matos; Jennifer L Clark; Andrew J Piper; Jenny Janusis; Leslie M Shaw
Journal:  J Biol Chem       Date:  2017-03-20       Impact factor: 5.157

4.  Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3β to regulate aerobic glycolysis.

Authors:  Justine Landis; Leslie M Shaw
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

5.  IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors.

Authors:  Holly A Porter; Anthony Perry; Chris Kingsley; Nhan L Tran; Achsah D Keegan
Journal:  Cancer Lett       Date:  2013-04-02       Impact factor: 8.679

Review 6.  Diversity of insulin and IGF signaling in breast cancer: Implications for therapy.

Authors:  Michael W Lero; Leslie M Shaw
Journal:  Mol Cell Endocrinol       Date:  2021-02-17       Impact factor: 4.102

7.  Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC).

Authors:  Andrew J Piper; Jennifer L Clark; Jose Mercado-Matos; Asia N Matthew-Onabanjo; Chung-Cheng Hsieh; Ali Akalin; Leslie M Shaw
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.